Achondroplasia, the most common form of dwarfism, is drawing increasing interest from pharmaceutical companies despite its rarity. Biomarin's VOXZOGO (vosoritide; a C-type natriuretic peptide; once-daily subcutaneous injection) is the only FDA-approved therapy for achondroplasia treatment. When it comes to BioMarin's approved therapy portfolio, VOXZOGO is the game-changer. It is also the reason why BioMarin's revenues have increased over the years. In 2023, the VOXZOGO's label was expanded to include children under five years old (all children with achondroplasia and open epiphyses), after it was approved in 2021 to treat achondroplasia (children ages five and o...
